PCF Science
@PCF_Science
The official Twitter account for scientific news from the Prostate Cancer Foundation. Follow us at @PCFNews @ http://PCF-science.bsky.social
ANNOUNCEMENT: RFA for 2025 @PCFnews team science Challenge Award Applications, to support investigations of metastatic, lethal #ProstateCancer in 6 specified topic areas. DEADLINE: May 5, 2025 Apply at: pcf.smartsimple.com View the RFA: res.cloudinary.com/pcf/images/v17…
The Mu Lab is using spatial transcriptomics/scRNA-seq-based examining, AI-based prediction, and 3D-cultured organoid-based testing to tackle questions in prostate cancer. @PCFnews @PCF_Science @YaleMed @Yale_Urology youtube.com/watch?v=asHVv7…
620 of 660 patients randomised in #PRIMARY2 🎯Bringing PSMA PET from staging to DIAGNOSIS 🏁The finishing line approaches Thank-you⭐investigators @ButeauJames @drlouiseemmett @DrDanielMoon @declangmurphy + many more Supported by @PeterMacCC @SVHSydney @PCF_Science @pros_tic…
Intraindividual epigenetic heterogeneity underlying phenotypic subtypes of advanced prostate cancer @NatureComms rdcu.be/euijO Team science led by Kei Mizuno #BeltranLab @DanaFarber_GU @PCF_Science
#VIOLET Study of Terbium-161 (161Tb) - first trial of Beta/Auger therapy. Recently presented #ASCO25. Now out in @TheLancetOncol : thelancet.com/journals/lanon… 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣Very few…
Thrilled to share our recent team science article unraveling TAM heterogeneity across PC disease spectrum & therapeutic targeting of "bad actor" SPP1+/TREM2+ TAM subsets in mCRPC: aacrjournals.org/mcr/article-ab… @PCF_Science @UChicagoHemOnc @UCCancerCenter @UChicagoCCB @TheVFoundation
🎙️Radio time! Join me TODAY @SIRIUSXM 110 @NYUDocs at 6-8pET for an exciting lineup! #ProstateCancer in SGM populations for #PrideMonth w/ Dr Tet Yap, #MensHealth Month infertility w @justindubinmd & sexual health w @SaveYourSexLife and lifestyle medicine w @drveggie @roclifemed
I loved this talk. Good ideas for collaborations.I would love to know how many collaborations and new projects have been born at a Coffey-Holden Academy over the years. It’s a couple per year just for me! @soulehoward1 @AndreaMiyahira
Big thanks to @soulehoward1 and @AndreaMiyahira for organizing a fantastic meeting in sunny California last week, bringing together PCF family and brilliant minds to tackle big questions in prostate cancer research! @PCFnews @PCF_Science #PCFAcademy
Beautiful talk by Dr. Isla Garraway on CIN as biomarker for prostate cancer, development of algorithm for pathology detection of CIN by @Bea0317Knudsen, CIN targeting in clinical trials. #PCFAcademy @PCF_Science
Prof. Mary-Claire King has been named the 2025 Princess of Asturias Award laureate for science — amazing recognition. Her work on the BRCA1/2 genes led to transforming cancer care, including for men with #ProstateCancer fpa.es/en/princess-of… @PCF_Science @criscancer
We are hiring a 👩🔬 Research Assistant 👨🔬 to work on cutting-edge dietary interventions to potentiate DNA damaging therapies in prostate cancer. Come working with us at the @CUSM_MUHC @McGillDeptSurg @mcgillu! Please share: bit.ly/43V72fs @UrologySBUR @PCF_Science
Michael Jung kicking off the @PCF_Science Coffey-Holden #ProstateCancer Academy discussing drug discovery His work to make enzalutamide has certainly made an impact!! 👏🏻👏🏻
#PCFAcademy @PCF_Science Day 2 session on Cell Death… uff.. each layer of understanding peels back to reveal deeper complexities.. the more I learn, I realize how little I really know 🫣
Breaking News: Darolutamide is now FDA-approved for mHSPC. It’s used with standard hormone therapy as part of combination treatment—the gold standard for mHSPC. Learn why this matters: pcf.org/the-new-standa…
Stunning research from @EdmondMKwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative…
Congrats #MichaelOng @Soum_Roy_RadOnc for oral Ab#5002 @ASCO #ASCO25👉bit.ly/43NyyfY👉Real-world IRONMAN registry of mHSPC #prostatecancer (n=1288 pts)👉PSA<0.02 after 6-12 mo of Rx had best prognosis (3-yr OS 92.7%)👇@Daniel_J_George @OncoAlert @urotoday @PCF_Science
On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the @ANZUPtrials phase II TheraP study, now published in @NatureMedicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across…
Just in from @ASCO #ASCO25 👉📢 Finally a T-cell engager in #prostatecancer mCRPC with minimal CRS syndrome (only grade 1, all outpatient dosing) and promising efficacy👇 Congrats #drbaldini @drmnstein and team @JCO_ASCO @OncoAlert @urotoday @PCF_Science
#VIOLET Study of Terbium-161 (Tb-161) Beta/Auger therapy @ASCO #ASCO25 First prospective trial of Terbium-161 in any tumour type 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣 Very few side effects: 1 grade 3…
Great discussions @asco #ProstateCancer posters #ASCO25 #PSMA+ #BCR is an indolent process & pts do NOT require urgent therapy in most cases We should be ⚠️ cautious about over-treatment 🔗shorturl.at/NtxdF Trial continues to accrue @theNCI clinicaltrials.gov/study/NCT05588…
Updated data from #PSMA monitoring study in #BCR #ProstateCancer @ASCO #ASCO25 Stop by & see our poster on Monday morning You can see what happens to this pt at 6 months 10+ LNs How would you have managed this case? Trial continues to accrue @theNCI clinicaltrials.gov/study/NCT05588…